Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458575 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
A Phase 1 study, sponsored by Centocor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00458575 is a Phase 1 study that was terminated before completion, run by Centocor. The registered enrollment target is 7 participants.
The verdict
NCT00458575, a Phase 1 study, was terminated before completion, sponsored by Centocor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the preliminary safety and immunogenicity (ability of an antigen to provoke immune response in the human body) of CNTO 2476, administered subretinally, in participants with advanced retinitis pigmentosa (RP; disease of the eye that leads to loss of vision and blindness) with either light perception only (LP) or hand motion (HM).
Interventions
- DRUG CNTO 2476
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-04 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458575
The ClinicalTrials.gov registry entry for NCT00458575 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CNTO 2476 is the first listed.
NCT00458575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458575 about?
NCT00458575 is a clinical study titled "A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa". The main purpose of this study is to evaluate the preliminary safety and immunogenicity (ability of an antigen to provoke immune response in the human body) of CNTO 2476, administered subretinally, in participants with advanced retinitis pigmentosa (RP; disease of the eye that leads to loss of visio...
What is the current status of trial NCT00458575?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2007-04. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00458575?
The interventions under investigation include: CNTO 2476 (DRUG).
Who is sponsoring clinical trial NCT00458575?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.